Yesterday, I started on the open label for LMTX, which the article below says had a 90% success rate in stopping the progression in its Phase 2 trials. I just completed the 18-month Phase 3 trial four weeks ago, and yes, while I still have limitations, I (and my neurologist) can attest that things have not gotten worse.
I am SO very grateful to Professor Claude Wischik, MD, PhD and everyone at TauRx and the San Francisco Clinical Research Center.
First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer’s Disease
